Bank of America’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-335
| Closed | -$2.51K | – | 6532 |
|
|
2025
Q4 | $2.51K | Sell |
335
-111
| -25% | -$626 | ﹤0.01% | 6378 |
|
|
2025
Q3 | $1.48K | Sell |
446
-124
| -22% | -$350 | ﹤0.01% | 7439 |
|
|
2025
Q2 | $1.72K | Buy |
570
+129
| +29% | +$390 | ﹤0.01% | 7454 |
|
|
2025
Q1 | $1.35K | Buy |
441
+5
| +1% | +$14 | ﹤0.01% | 7381 |
|
|
2024
Q4 | $1.04K | Buy |
436
+24
| +6% | +$65 | ﹤0.01% | 7284 |
|
|
2024
Q3 | $1.17K | Sell |
412
-4
| -1% | -$12 | ﹤0.01% | 7212 |
|
|
2024
Q2 | $1.23K | Buy |
416
+206
| +98% | +$566 | ﹤0.01% | 7201 |
|
|
2024
Q1 | $615 | Sell |
210
-6
| -3% | -$19 | ﹤0.01% | 7258 |
|
|
2023
Q4 | $541 | Buy |
216
+6
| +3% | +$18 | ﹤0.01% | 7277 |
|
|
2023
Q3 | $655 | Sell |
210
-1,500
| -88% | -$5.58K | ﹤0.01% | 7287 |
|
|
2023
Q2 | $7.87K | Buy |
1,710
+396
| +30% | +$1.99K | ﹤0.01% | 6916 |
|
|
2023
Q1 | $9.31K | Sell |
1,314
-706
| -35% | -$5.24K | ﹤0.01% | 6932 |
|
|
2022
Q4 | $12.9K | Sell |
2,020
-1,140
| -36% | -$12.6K | ﹤0.01% | 6861 |
|
|
2022
Q3 | $46K | Sell |
3,160
-2,733
| -46% | -$47.3K | ﹤0.01% | 6712 |
|
|
2022
Q2 | $106K | Buy |
5,893
+4,769
| +424% | +$108K | ﹤0.01% | 6439 |
|
|
2022
Q1 | $33K | Sell |
1,124
-550
| -33% | -$17.6K | ﹤0.01% | 7334 |
|
|
2021
Q4 | $73K | Buy |
1,674
+281
| +20% | +$16.2K | ﹤0.01% | 7029 |
|
|
2021
Q3 | $99K | Buy |
1,393
+74
| +6% | +$6.8K | ﹤0.01% | 6733 |
|
|
2021
Q2 | $151K | Sell |
1,319
-1,234
| -48% | -$120K | ﹤0.01% | 6271 |
|
|
2021
Q1 | $265K | Buy |
2,553
+1,935
| +313% | +$184K | ﹤0.01% | 5831 |
|
|
2020
Q4 | $29K | Buy |
618
+614
| +15,350% | +$22.5K | ﹤0.01% | 6501 |
|
|
2020
Q3 | $0 | Sell |
4
-489
| -99% | -$14K | ﹤0.01% | 7092 |
|
|
2020
Q2 | $19K | Buy |
493
+460
| +1,394% | +$23.8K | ﹤0.01% | 6282 |
|
|
2020
Q1 | $2K | Sell |
33
-94
| -74% | -$4.61K | ﹤0.01% | 6639 |
|
|
2019
Q4 | $6K | Sell |
127
-187
| -60% | -$6.75K | ﹤0.01% | 6735 |
|
|
2019
Q3 | $13K | Buy |
314
+100
| +47% | +$3.93K | ﹤0.01% | 6672 |
|
|
2019
Q2 | $10K | Sell |
214
-176
| -45% | -$14.6K | ﹤0.01% | 6731 |
|
|
2019
Q1 | $31K | Buy |
+390
| New | +$25.1K | ﹤0.01% | 6371 |
|
|
2018
Q3 | – | Sell |
-159
| Closed | -$8K | – | 7407 |
|
|
2018
Q2 | $8K | Buy |
159
+132
| +489% | +$6.5K | ﹤0.01% | 6707 |
|
|
2018
Q1 | $2K | Sell |
27
-8
| -23% | -$529 | ﹤0.01% | 6900 |
|
|
2017
Q4 | $3K | Buy |
35
+7
| +25% | +$789 | ﹤0.01% | 6818 |
|
|
2017
Q3 | $4K | Buy |
28
+15
| +115% | +$1.57K | ﹤0.01% | 6780 |
|
|
2017
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 6827 |
|
|
2017
Q1 | $2K | Sell |
13
-10
| -43% | -$1.16K | ﹤0.01% | 6795 |
|
|
2016
Q4 | $3K | Buy |
23
+9
| +64% | +$991 | ﹤0.01% | 6787 |
|
|
2016
Q3 | $1K | Sell |
14
-18
| -56% | -$1.45K | ﹤0.01% | 6946 |
|
|
2016
Q2 | $2K | Sell |
32
-110
| -77% | -$10.3K | ﹤0.01% | 6900 |
|
|
2016
Q1 | $13K | Buy |
+142
| New | +$12.6K | ﹤0.01% | 6302 |
|
Other funds holding IMDX
BC
AIC
PVI
VCM
HCM
FIA
VFT
Bank of America's IMDX Position: Q1 2026 in Review
Bank of America sold out of Insight Molecular Diagnostics (IMDX) in Q1 2026, closing a stake of 335 shares — an estimated $2.51K sold.
Bank of America first reported a position in IMDX in Q1 2016 and held it in 38 quarters. The position peaked at $265K in Q1 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.
- Bank of America reported no remaining Insight Molecular Diagnostics position as of Q1 2026 after selling out during the quarter.
- Bank of America sold 335 Insight Molecular Diagnostics shares in Q1 2026, an estimated $2.51K.
- Bank of America first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 38 quarters.
- Bank of America's Insight Molecular Diagnostics position peaked at $265K in Q1 2021.
- 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.